Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received Certificate of Suitability (CEP) of gadobutrol API issued by European Directorate for the Quality of Medicines & HealthCare (EDQM).
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received written confirmation for active substance exported to EU (hereinafter referred to as “WC”) of gadobutrol API and certificate of a pharmaceutical product (hereinafter referred to as “COPP”) of cyclophosphamide API issued by Anhui NMPA.
From Milan to the ancient capital Xi'an, after participating in the 35th CPHI Milan 2024 (World Pharmaceutical API Exhibition) held at the Milan Exhibition Center in Italy, Poly witnessed the grand opening of the 91st CPHI/Intermediates/Packaging/Equipment Fair from October 16-18, 2024.
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received Notice of Approval for Listing Application of Gadoteridol API issued by National Medical Products Administration (hereinafter referred to as “NMPA”).
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received Notice of Approval for Listing Application of Memantine Hydrochloride API issued by National Medical Products Administration (hereinafter referred to as “NMPA”).
